Life ScienceCompany
Applied StemCell - Gene Editing Platform & Oncology Product Portfolio Ownership
Who owns Applied StemCell - Gene Editing Platform & Oncology Product Portfolio?
Applied StemCell - Gene Editing Platform & Oncology Product Portfolio is owned by Abcam. It was acquired on January 30, 2020.
Applied StemCell - Gene Editing Platform & Oncology Product Portfolio Business Overview
Where is Applied StemCell - Gene Editing Platform & Oncology Product Portfolio headquartered?
Applied StemCell - Gene Editing Platform & Oncology Product Portfolio is headquartered in Milpitas, California.
What sector is Applied StemCell - Gene Editing Platform & Oncology Product Portfolio in?
Applied StemCell - Gene Editing Platform & Oncology Product Portfolio is a life science company.
Life Science M&A Summary in 2020
Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.
Join Mergr to view all 292 acquisitions of life science companies in 2020, including 24 acquisitions by private equity firms, and 268 by strategics.